A naukri.com initiative
Bioengineer
1w
299
Image Credit: Bioengineer
Breakthrough Discoveries in Bladder Cancer Treatment Pave the Way for Enhanced Immunotherapies
- A recent study by Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center sheds light on how BCG immunotherapy for bladder cancer impacts the immune system beyond local effects.
- BCG, originally a tuberculosis vaccine, has been a pivotal immunotherapy in early-stage bladder cancer treatment for decades.
- The study reveals that BCG not only affects the bladder locally but also stimulates systemic immune responses via bone marrow.
- Researchers found that BCG reprograms hematopoietic stem cells in the bone marrow, enhancing the production of myeloid cells for improved immune defense against tumors.
- Innate immunity plays a crucial role in the body's rapid response to threats, and BCG enhances this innate arm of immunity to combat cancer cells effectively.
- The study utilized advanced techniques like single-cell sequencing to understand how BCG therapy alters gene expression in progenitor cells, leading to enhanced tumor-fighting capabilities.
- BCG demonstrated systemic effects by translocating from the bladder to the bone marrow, where it influenced the immune response against cancer.
- Combining BCG with checkpoint inhibitors showed synergistic effects in mouse models, resulting in better tumor shrinkage and prolonged survival rates.
- Targeting bone marrow to reprogram innate immunity could improve the efficacy of cancer immunotherapies across different cancer types, presenting new therapeutic avenues.
- While these findings are promising, further research is needed to optimize bone marrow reprogramming for therapeutic benefits and explore its application in cancers beyond bladder cancer.
Read Full Article
17 Likes
For uninterrupted reading, download the app